CompletedPhase 3Results posted

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Lead sponsor

Adrian Vella

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04459338

Org study ID20-003995

Secondary ID5R01DK126206-03

Timeline

Milestones

Study first posted2020-07-07actual

Study start2021-03-04actual

Primary completion2022-06-14actual

Study completion2022-06-14actual

Last update posted2023-06-09actual

Results first posted2023-06-09actual

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age25 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•20 weight-stable, non-diabetic subjects

Exclusion criteria

•Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).

•HbA1c ≥5.9%

•Use of glucose-lowering agents.

•For female subjects: positive pregnancy test at the time of enrollment or study

•History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.

•Active systemic illness or malignancy.

•Symptomatic macrovascular or microvascular disease.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.